Sector landing page

Pharma valuations

pharma-franchise cohort (Indian domestic-OTC + branded chronic-care MNCs). Terminal growth lifts to 5.5% to reflect India healthcare nominal-spend tailwind and pricing-power durability. CDMO names (DIVISLAB, SYNGENE) use a separate 4.5% lift under the same framework. Hospital chains are tracked under a sibling cohort (MAXHEALTH, FORTIS, APOLLOHOSP, etc.) at 5.5%.

Tickers

Median MoS

-24.9%

across 13 stocks

Median score

across 13 stocks

Median ROE

15.6%

across 13 stocks

Verdict distribution

Undervalued1

Fairly valued5

Overvalued5

Cohort constituents

	Name			FV	Price
ABBOTINDIA	Abbott India Limited	58	-16.7	21897.19	26280.00	Fairly valued
GLAXO	GlaxoSmithKline Pharmaceuticals Limited	58	-11.6	1875.18	2121.50	Fairly valued
DRREDDY	Dr. Reddy's Laboratories Limited	55	12.1	1429.15	1275.40	Fairly valued
SUNPHARMA	Sun Pharmaceutical Industries	53	-24.9	1357.90	1807.70	Fairly valued
ERIS	Eris Lifesciences Limited	50	-47.0	744.03	1404.60	data_limited
CIPLA	Cipla Limited	45	-12.3	1218.32	1389.40	Fairly valued
PFIZER	Pfizer Limited	43	-17.4	3725.27	4509.20	avoid
MANKIND	Mankind Pharma Limited	40	-55.1	1070.14	2381.10	Overvalued
TORNTPHARM	Torrent Pharmaceuticals Limited	40	-63.2	1680.76	4571.20	Overvalued
DIVISLAB	Divi's Laboratories Limited	40	-62.1	2516.13	6636.00	Overvalued
GLAND	Gland Pharma Limited	40	-55.7	1008.65	2275.60	Overvalued
SANOFI	SANOFI INDIA LIMITED	40	71.6	5355.87	3120.90	Undervalued
AJANTPHARM	Ajanta Pharma Limited	32	-57.8	1322.02	3131.00	Overvalued